12:32 PM
Mar 05, 2018
 |  BC Week In Review  |  Company News  |  Deals

Celgene licenses drug modifying tech from Amunix

Amunix Operating Inc. (Mountain View, Calif.) licensed its XTEN and ProTIA technologies to Celgene Corp. (NASDAQ:CELG) to discover and develop drugs against...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >